文献速递哮喘

肥胖与健康体重哮喘患者药物使用比较:系统综述与荟萃分析

Asthma medication use in obese and healthy weight asthma: systematic review/meta-analysis.
PubMed 文献 · Eur Respir J · 2021-03-04

该系统综述与荟萃分析检索截至2019年7月的英文研究,比较肥胖(BMI≥30 kg·m⁻²)与健康体重(BMI<25 kg·m⁻²)成人哮喘患者的药物使用。结果显示肥胖者更常使用短效β2激动剂(OR 1.75,95%CI 1.17-2.60;p=0.006)和维持口服糖皮质激素(OR 1.86,95%CI 1.49-2.31;p<0.001),吸入糖皮质激素剂量更高(平均差208.14 μg·d⁻¹,95%CI 107.01-309.27;p<0.001),FEV1%预计值更低(平均差-5.32%,95%CI -6.75至-3.89;p<0.001),但FEV1/FVC比值无显著差异。

要点

  • 肥胖哮喘患者短效β2激动剂使用风险增加(OR 1.75)。
  • 肥胖哮喘患者维持口服糖皮质激素使用风险增加(OR 1.86)。
  • 肥胖哮喘患者吸入糖皮质激素日剂量更高(平均差208.14 μg·d⁻¹)。

核心结论

  • 肥胖哮喘患者所有纳入的哮喘药物类别使用率更高、吸入糖皮质激素剂量更高,尽管FEV1更低而FEV1/FVC比值相似。
  • 需要更好理解驱动药物使用增加的因素以改善该亚组哮喘患者的结局。

研究设计与样本

  • 系统综述与荟萃分析,检索CINAHL、Cochrane、Embase和MEDLINE截至2019年7月的英文文献。
  • 纳入记录肥胖(BMI≥30 kg·m⁻²)与健康体重(BMI<25 kg·m⁻²)成人哮喘患者药物使用或剂量的研究。
  • 使用批判性评估清单审查纳入研究的方法学质量,采用卡方检验检查异质性,基于已发表方案(PROSPERO CRD42020148671)实施。

主要发现

  • 肥胖受试者更可能使用短效β2激动剂(OR 1.75,95%CI 1.17-2.60;p=0.006,I²=41%)。
  • 肥胖受试者更可能使用维持口服糖皮质激素(OR 1.86,95%CI 1.49-2.31;p<0.001,I²=0%)。
  • 肥胖受试者吸入糖皮质激素剂量(μg·d⁻¹)显著更高(平均差208.14,95%CI 107.01-309.27;p<0.001,I²=74%)。
  • 肥胖受试者FEV1%预计值显著更低(平均差-5.32%,95%CI -6.75至-3.89;p<0.001,I²=42%),但FEV1/FVC比值组间无显著差异。

临床怎么用

  • 临床应关注肥胖哮喘患者药物使用增加及吸入糖皮质激素剂量偏高的现象。
  • 对肥胖哮喘患者需综合评估药物使用驱动因素以优化管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is a common comorbidity in asthma and associated with poorer asthma control, more frequent/severe exacerbations, and reduced response to asthma pharmacotherapy. OBJECTIVE: This review aims to compare use of all classes of asthma medications in obese (body mass index (BMI) ≤30 kg·m-2) versus healthy-weight (BMI <25 kg·m-2) subjects with asthma. DESIGN: Databases including CINAHL (Cumulative Index to Nursing and Allied Health Literature), Cochrane, Embase and MEDLINE were searched up to July 2019 for English-language studies that recorded medication use or dose in obese and healthy-weight adults with asthma. A critical appraisal checklist was utilised for scrutinising methodological quality of eligible studies. Meta-analysis was performed and heterogeneity was examined with the use of the Chi-squared test. This review was conducted based on a published protocol (www.crd.york.ac.uk/PROSPERO CRD42020148671). RESULTS: Meta-analysis showed that obese subjects are more likely to use asthma medications, including short-acting β2-agonists (OR 1.75, 95% CI 1.17-2.60; p=0.006, I2=41%) and maintenance oral corticosteroids (OR 1.86, 95% CI 1.49-2.31; p<0.001, I2=0%) compared to healthy-weight subjects. Inhaled corticosteroid (ICS) dose (µg·day-1) was significantly higher in obese subjects (mean difference 208.14, 95% CI 107.01-309.27; p<0.001, I2=74%). Forced expiratory volume in 1 s (FEV1) % predicted was significantly lower in obese subjects (mean difference -5.32%, 95% CI -6.75--3.89; p<0.001, I2=42%); however, no significant differences were observed in FEV1/forced vital capacity (FVC) ratio between groups. CONCLUSIONS: We found that obese subjects with asthma have higher use of all included asthma medication classes and higher ICS doses than healthy-weight asthma subjects, despite lower FEV1 and a similar FEV1/FVC %. A better understanding of the factors driving increased medication use is required to improve outcomes in this subgroup of asthmatics.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Thompson CA, Eslick SR, Berthon BS, et al. Asthma medication use in obese and healthy weight asthma: systematic review/meta-analysis. Eur Respir J. 2021. PMID: 32943399. doi:10.1183/13993003.00612-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。